title: Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
abstract: BACKGROUND
  Pancreatic cancer, a particularly deadly form of malignancy, has increased in the last decade worldwide. The purpose of this study is to identify markers for determining and identifying possible long-term survivors in cases of advanced pancreatic cancer.
  
  
  METHODS
  117 patients with pancreatic ductal carcinoma, including 89 with invasive tubular adenocarcinoma of the pancreas, Japan Pancreas Society (JPS) stage III-IVb patients, who underwent tumor resection between 1986 and 2006.
  
  
  RESULTS
  Univariate prognostic analyses of the 5-year disease-specific survival (DSS) revealed that JPS stage (P < 0.0001), preoperative serum carbohydrate antigen 19-9 (CA19-9) level (preCA19-9; P < 0.0001), dissected peripancreatic tissue margin (DPM; P < 0.0001), residual tumor (R factor; P = 0.0007), lymph node metastasis density over 10% (ND10; P = 0.006), volume of the stromal connective tissue (stroma factor; P = 0.008), growth pattern (P = 0.01), and histology (P = 0.03) were all significantly associated with poor outcome in advanced pancreatic cancer. Multivariate logistic analysis confirmed that preCA19-9 [P = 0.0006, relative risk (RR) = 2.16] and DPM (P = 0.04, RR = 1.62) were prognostic factors that remained, independent of JPS stage (P = 0.001). The higher preCA19-9 was, the worse the prognosis was. Astonishingly, among JPS stage III cases, 76.9% of the patients with preCA19-9 below 37 U/ml survived more than 5 years. This, combined with an analysis of DPM, allowed us to identify those with the potentiality for long-term survival.
  
  
  CONCLUSIONS
  Our results reveal for the first time that it is possible with JPS stage III-IVb invasive tubular adenocarcinomas of the pancreas to differentiate prognostic groups and potential survival rates, like with other cancers.
authors.affiliation: Department of Surgery, Medical School, Kitasato University Hospital, Sagamihara, Kanagawa, Japan.
authors.forename: Mina
authors.initials: M
authors.lastname: Waraya
authors.forename: Keishi
authors.initials: K
authors.lastname: Yamashita
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Katagiri
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Ishii
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Kazunori
authors.initials: K
authors.lastname: Furuta
authors.forename: Masahiko
authors.initials: M
authors.lastname: Watanabe
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D000368:Aged; D018395:CA-19-9 Antigen / Q000097:blood*; D021441:Carcinoma, Pancreatic Ductal / Q000097:blood / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D011379:Prognosis
chemical_list: D018395:CA-19-9 Antigen